Current pharmacotherapy options for gastritis

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 18, 2012, Pages 2625-2636

  Den Hollander, Wouter J ^a   Kuipers, Ernst J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Gastritis; Gastropathy; Helicobacter pylori; Pharmacotherapy

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; BISMUTH DERIVATIVE; CLARITHROMYCIN; DOXYCYCLINE; FURAZOLIDONE; HYDROTALCITE; LANSOPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; MISOPROSTOL; NITAZOXANIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; RABEPRAZOLE; RIFABUTIN; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; AUTOIMMUNE ATROPHIC GASTRITIS; BILE REFLUX GASTRITIS; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG INDUCED GASTRITIS; EOSINOPHILIC GASTRITIS; ERADICATION THERAPY; GASTRITIS; HELICOBACTER INFECTION; HUMAN; LYMPHOCYTIC GASTRITIS; META ANALYSIS (TOPIC); NONHUMAN; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION; SYSTEMATIC REVIEW (TOPIC); TREATMENT INDICATION;

ANTACIDS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; DRUG RESISTANCE, BACTERIAL; EVIDENCE-BASED MEDICINE; GASTRIC MUCOSA; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS;

EID: 84870234302     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.747510     Document Type: Review

References (108)

1. Hojgaard L, Matzen P, Christoffersen P. Gastritis-a clinical entity? Scand J Gastroenterol Suppl 1987;128:90-3
2. Redeen S, Petersson F, Jonsson KA, et al. Relationship of gastroscopic features to histological findings in gastritis and Helicobacter pylori infection in a general population sample. Endoscopy 2003;35:946-50
3. Calabrese C, Di Febo G, Brandi G, et al. Correlation between endoscopic features of gastric antrum, histology and Helicobacter pylori infection in adults. Ital J Gastroenterol Hepatol 1999;31:359-65
4. Loffeld RJ. Diagnostic value of endoscopic signs of gastritis: with special emphasis to nodular antritis. Neth J Med 1999;54:96-100
5. Yela MC, Manzano ML, Rodriguez-Munoz S, et al. Assessment of the usefulness of endoscopic signs in Helicobacter pylori associated gastritis. Rev Esp Enferm Dig 1997;89:3-12
6. Yagi K, Honda H, Yang JM, et al. Magnifying endoscopy in gastritis of the corpus. Endoscopy 2005;37:660-6
7. Sipponen P, Price AB. The sydney system for classification of gastritis 20 years ago. J Gastroenterol Hepatol 2011;26(Suppl 1):31-4
8. Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161-81
9. Rugge M, Meggio A, Pennelli G, et al. Gastritis staging in clinical practice: the OLGA staging system. Gut 2007;56:631-6
10. Rugge M, Pennelli G, Pilozzi E, et al. Gastritis: the histology report. Dig Liver Dis 2011;43(Suppl 4):S373-84
11. Capelle LG, de Vries AC, Haringsma J, et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc 2010;71:1150-8
12. Rugge M, Fassan M, Pizzi M, et al. Operative link for gastritis assessment vs operative link on intestinal metaplasia assessment. World J Gastroenterol 2011;17:4596-601
13. Dinis-Ribeiro M, Areia M, de Vries AC, et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 2012;44:74-94
14. Sipponen P. Chronic gastritis in former times and now. Helicobacter 2007;12(Suppl 2):16-21
15. McColl KE. Clinical practice. Helicobacter pylori infection. N Engl J Med 2010;362:1597-604
16. Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 2006;19:449-90
17. Post PN, Kuipers EJ, Meijer GA. Declining incidence of peptic ulcer but not of its complications: a nation-wide study in The Netherlands. Aliment Pharmacol Ther 2006;23:1587-93
18. de Vries AC, Meijer GA, Looman CW, et al. Epidemiological trends of pre-malignant gastric lesions: a long-term nationwide study in the Netherlands. Gut 2007;56:1665-70
19. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002;347:1175-86
20. den Hoed CM, Vila AJ, Holster IL, et al. Helicobacter pylori and the birth cohort effect: evidence for stabilized colonization rates in childhood. Helicobacter 2011;16:405-9
21. Crabtree JE. Gastric mucosal inflammatory responses to Helicobacter pylori. Aliment Pharmacol Ther 1996;10(Suppl 1):29-37
22. Lauwers GY, Fujita H, Nagata K, et al. Pathology of non-Helicobacter pylori gastritis: extending the histopathologic horizons. J Gastroenterol 2010;45:131-45
23. D'Elios MM, Appelmelk BJ, Amedei A, et al. Gastric autoimmunity: the role of Helicobacter pylori and molecular mimicry. Trends Mol Med 2004;10:316-23
24. Veijola LI, Oksanen AM, Sipponen PI, et al. Association of autoimmune type atrophic corpus gastritis with Helicobacter pylori infection. World J Gastroenterol 2010;16:83-8
25. Carpenter HA, Talley NJ. Gastroscopy is incomplete without biopsy: clinical relevance of distinguishing gastropathy from gastritis. Gastroenterology 1995;108:917-24
26. Niemela S. Duodenogastric reflux in patients with upper abdominal complaints or gastric ulcer with particular reference to reflux-associated gastritis. Scand J Gastroenterol 1985;115(Suppl):1-56
27. Chen H, Li X, Ge Z, et al. Rabeprazole combined with hydrotalcite is effective for patients with bile reflux gastritis after cholecystectomy. Can J Gastroenterol 2010;24:197-201
28. Freeman HJ. Adult eosinophilic gastroenteritis and hypereosinophilic syndromes. World J Gastroenterol 2008;14:6771-3
29. Tan AC, Kruimel JW, Naber TH. Eosinophilic gastroenteritis treated with non-enteric-coated budesonide tablets. Eur J Gastroenterol Hepatol 2001;13:425-7
30. Madisch A, Miehlke S, Neuber F, et al. Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy-a randomized, double-blind, placebo-controlled multicentre trial. Aliment Pharmacol Ther 2006;23:473-9
31. Selgrad M, Kandulski A, Malfertheiner P. Dyspepsia and Helicobacter pylori. Dig Dis 2008;26:210-14
32. Laine L, Schoenfeld P, Fennerty MB. Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. Ann Intern Med 2001;134:361-9
33. Moayyedi P, Soo S, Deeks J, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006;CD002096
34. Marshall BJ, Goodwin CS, Warren JR, et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988;2:1437-42
35. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992;52:6735-40
36. Parsonnet J, Hansen S, Rodriguez L, et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med 1994;330:1267-71
37. Capelle LG, de Vries AC, Looman CW, et al. Gastric MALT lymphoma: epidemiology and high adenocarcinoma risk in a nation-wide study. Eur J Cancer 2008;44:2470-6
38. Zullo A, Hassan C, Cristofari F, et al. Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol 2010;8:105-10
39. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht IV/Florence consensus report. Gut 2012;61:646-64
40. Valle J, Seppala K, Sipponen P, et al. Disappearance of gastritis after eradication of Helicobacter pylori. A morphometric study. Scand J Gastroenterol 1991;26:1057-65
41. Malfertheiner P. Gastric atrophy reversible or irreversible after Helicobacter pylori eradication-an open question. Digestion 2011;83:250-2
42. Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, et al. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: Results of a randomised controlled trial. Gut 2004;53:12-20
43. Wang J, Xu L, Shi R, et al. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis. Digestion 2011;83:253-60
44. Rokkas T, Pistiolas D, Sechopoulos P, et al. The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis. Helicobacter 2007;12(Suppl 2):32-8
45. De Vries AC, Kuipers EJ. Review article: helicobacter pylori eradication for the prevention of gastric cancer. Aliment Pharmacol Ther 2007;26(Suppl 2):25-35
46. Fuccio L, Zagari RM, Eusebi LH, et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med 2009;151:121-8
47. de Vries AC, Kuipers EJ, Rauws EA. Helicobacter pylori eradication and gastric cancer: when is the horse out of the barn? Am J Gastroenterol 2009;104:1342-5
48. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010;59:1143-53
49. Graham DY. Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology 1998;115:1272-7
50. Romano M, Iovene MR, Russo MI, et al. Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical isolates. J Clin Pathol 2008;61:1112-15
51. Megraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007;20:280-322
52. Occhialini A, Urdaci M, Doucet-Populaire F, et al. Macrolide resistance in Helicobacter pylori: rapid detection of point mutations and assays of macrolide binding to ribosomes. Antimicrob Agents Chemother 1997;41:2724-8
53. Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2012; Epub ahead of print
54. De Francesco V, Giorgio F, Hassan C, et al. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis 2010;19:409-14
55. Furuta T, Graham DY. Pharmacologic aspects of eradication therapy for Helicobacter pylori Infection. Gastroenterol Clin North Am 2010;39:465-80
56. Hunfeld NG, Touw DJ, Mathot RA, et al. A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism. Aliment Pharmacol Ther 2010;31:150-9
57. Padol S, Yuan Y, Thabane M, et al. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol 2006;101:1467-75
58. Serrano DR, Torrado S, Torrado-Santiago S, et al. The influence of CYP2C19 genetic polymorphism on the pharmacokinetics/pharmacodynamics of proton pump inhibitor-containing Helicobacter pylori treatments. Curr Drug Metab 2012; Epub ahead of print
59. Furuta T, Shirai N, Kodaira M, et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther 2007;81:521-8
60. Chey WD, Wong BC; Practice Parameters Committee of the American College of G. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007;102:1808-25
61. Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009;24:1587-600
62. Vakil N. Helicobacter pylori: factors affecting eradication and recurrence. Am J Gastroenterol 2005;100:2393-4
63. Vallve M, Vergara M, Gisbert JP, et al. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. Aliment Pharmacol Ther 2002;16:1149-56
64. Fuccio L, Minardi ME, Zagari RM, et al. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007;147:553-62
65. Megraud F. The challenge of Helicobacter pylori resistance to antibiotics: the comeback of bismuth-based quadruple therapy. Therap Adv Gastroenterol 2012;5:103-9
66. Ford AC, Malfertheiner P, Giguere M, et al. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol 2008;14:7361-70
67. Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol 2012;5:23-34
68. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007;26:343-57
69. Luther J, Higgins PD, Schoenfeld PS, et al. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol 2010;105:65-73
70. Zullo A, Rinaldi V, Winn S, et al. A new highly effective short-term therapy schedule for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000;14:715-18
71. Luther J, Chey WD. Sequential therapy for Helicobacter pylori: a two for one deal that's worth the extra effort? Gastroenterology 2009;136:720-2
72. Gisbert JP, Calvet X, O'Connor A, et al. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol 2010;44:313-25
73. Gisbert JP, Calvet X, O'Connor JP, et al. The sequential therapy regimen for Helicobacter pylori eradication. Expert Opin Pharmacother 2010;11:905-18
74. Vaira D, Zullo A, Vakil N, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med 2007;146:556-63
75. Kim YS, Kim SJ, Yoon JH, et al. Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea. Aliment Pharmacol Ther 2011;34:1098-105
76. Park HG, Jung MK, Jung JT, et al. Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naive patients. Aliment Pharmacol Ther 2012;35:56-65
77. Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med 2008;148:923-31
78. Zullo A, Hassan C, Ridola L, et al. Standard triple and sequential therapies for Helicobacter pylori eradication: an update. Eur J Intern Med 2012; Epub ahead of print
79. Romano M, Cuomo A, Gravina AG, et al. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut 2010;59:1465-70
80. Zullo A, Hassan C, D'Ercole C, et al. Clarithromycin or levofloxacin in the sequential therapy for H. pylori eradication? Aliment Pharmacol Ther 2010;31:1248-9
81. Zullo A, De Francesco V, Vaira D. Sequential therapy for Helicobacter pylori eradication: is levofloxacin better? Gut 2011;60:1604
82. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008;52:1502-17
83. Lanza FL, Chan FK, Quigley EM, et al. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009;104:728-38
84. Morgner A, Miehlke S, Labenz J. Esomeprazole: prevention and treatment of NSAID-induced symptoms and ulcers. Expert Opin Pharmacother 2007;8:975-88
85. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241-9
86. Graham DY, Agrawal NM, Campbell DR, et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: Results of a double-blind, randomized, multicenter, active-and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 2002;162:169-75
87. Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002;CD002296
88. Lazzaroni M, Porro GB. Management of NSAID-induced gastrointestinal toxicity: focus on proton pump inhibitors. Drugs 2009;69:51-69
89. Ekstrom P, Carling L, Wetterhus S, et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal antiinflammatory drug therapy. A Nordic multicentre study. Scand J Gastroenterol 1996;31:753-8
90. Hooper L, Brown TJ, Elliott R, et al. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal antiinflammatory drugs: systematic review. BMJ 2004;329:948
91. Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006;101:701-10
92. van Soest EM, Valkhoff VE, Mazzaglia G, et al. Suboptimal gastroprotective coverage of NSAID use and the risk of upper gastrointestinal bleeding and ulcers: an observational study using three European databases. Gut 2011;60:1650-9
93. Barkun AN, Bardou M, Kuipers EJ, et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2010;152:101-13
94. Targownik LE, Metge CJ, Leung S, et al. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. Gastroenterology 2008;134:937-44
95. Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998;338:719-26
96. Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998;338:727-34
97. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002;359:14-22
98. Chan FK, To KF, Wu JC, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002;359:9-13
99. Santarelli L, Gabrielli M, Candelli M, et al. Post-cholecystectomy alkaline reactive gastritis: a randomized trial comparing sucralfate versus rabeprazole or no treatment. Eur J Gastroenterol Hepatol 2003;15:975-9
100. Toh BH, Chan J, Kyaw T, et al. Cutting edge issues in autoimmune gastritis. Clin Rev Allergy Immunol 2012;42:269-78
101. Biondo M, Field J, Toh BH, et al. Prednisolone promotes remission and gastric mucosal regeneration in experimental autoimmune gastritis. J Pathol 2006;209:384-91
102. Landgren AM, Landgren O, Gridley G, et al. Autoimmune disease and subsequent risk of developing alimentary tract cancers among 4.5 million US male veterans. Cancer 2011;117:1163-71
103. Hsing AW, Hansson LE, McLaughlin JK, et al. Pernicious anemia and subsequent cancer. A populationbased cohort study. Cancer 1993;71:745-50
104. Hirota WK, Zuckerman MJ, Adler DG, et al. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc 2006;63:570-80
105. Khan S, Orenstein SR. Eosinophilic gastroenteritis. Gastroenterol Clin North Am 2008;37:333-48, v
106. Niemela S, Karttunen TJ, Kerola T. Treatment of Helicobacter pylori in patients with lymphocytic gastritis. Hepatogastroenterology 2001;48:1176-8
107. Makinen JM, Niemela S, Kerola T, et al. Epithelial cell proliferation and glandular atrophy in lymphocytic gastritis: effect of H pylori treatment. World J Gastroenterol 2003;9:2706-10
108. Rugge M, Genta RM, Group O. Staging gastritis: an international proposal. Gastroenterology 2005;129:1807-8